CJC-1295 DAC vs no DAC: identity before research claims
CJC-1295 in the foundational long-acting studies included an albumin-binding chemical extension. A no-DAC designation describes material without that feature, so its identity and evidence must be assessed separately. Neither a shared name nor a citation to a human study establishes which molecule is present in a catalogue vial.
What the DAC distinction changes
Jetté and colleagues’ 2005 research described CJC-1295 as a modified human growth-hormone-releasing factor fragment, GRF(1–29), with an additional maleimido-lysine derivative at its C terminus. The reactive group allowed covalent attachment to albumin, a blood protein. This chemical design matters when interpreting the compound’s prolonged presence in circulation.
The researchers examined albumin conjugates in cultured rat pituitary cells and studied the compounds in rats. Their findings connect a defined structure with experimental activity and persistence. They do not establish that every later product carrying the CJC-1295 name has the same extension.
Why “no DAC” needs a complete specification
Names such as no DAC and modified GRF(1–29) are useful starting points, but a material assessment should record the sequence and terminal modifications explicitly. An instructive 2010 analytical paper by Henninge and colleagues examined an unknown preparation using high-resolution tandem mass spectrometry. It found a 29-residue peptide with a C-terminal amide, with a proposed sequence consistent with material then marketed as CJC-1295.
That is a finding about one preparation. It illustrates the naming problem without resolving the contents of any current supplier’s product. Treat DAC status as a property to document, rather than something established by an abbreviated label or a search result.
What the human CJC-1295 studies measured
Teichman and colleagues reported two randomised, placebo-controlled studies in healthy adults, lasting 28 and 49 days. They measured CJC-1295 pharmacokinetics and circulating growth hormone, or GH, and insulin-like growth factor I, or IGF-I. The reported sustained hormone responses concerned the investigational long-acting compound.
These endpoints establish physiological activity within the studied conditions. They do not, by themselves, establish improved recovery, body composition, sleep or longevity. The abstract’s report that no serious adverse reactions occurred in those studies also cannot establish long-term safety or validate independently supplied material.
Preserved pulses do not mean an unchanged hormone profile
Ionescu and Frohman examined overnight GH patterns in healthy men before and after long-acting, albumin-binding CJC-1295. Pulsatility persisted, but trough and mean GH concentrations increased. The study therefore should not be reduced to a claim that the entire hormone pattern remained unchanged.
It also was not a head-to-head test of DAC and no-DAC materials. Using its pulsatility finding to promote a differently specified peptide would add a comparison the experiment did not make.
A practical map of the evidence
Read the material and the question together. A strong answer to an analytical question can coexist with unanswered clinical questions. This selected evidence map is not a complete review of development history or current regulatory status.
| Evidence | What it addresses | What it does not establish |
|---|---|---|
| Jetté, 2005: cells and rats | Albumin-binding design and experimental activity. | Identity of a current retail sample. |
| Henninge, 2010: sample analysis | A 29-residue amidated peptide in one preparation. | A universal meaning for every CJC label. |
| Teichman, 2006: human trials | Exposure and GH/IGF-I responses. | General clinical benefits or no-DAC equivalence. |
| Ionescu, 2006: human physiology | Pulses alongside changes in trough and mean GH. | A DAC-versus-no-DAC comparison. |
CJC-1295/ipamorelin requires an additional evidence check
Adding ipamorelin creates a separate material and research question. Raun and colleagues’ foundational ipamorelin paper studied rat pituitary cells, rats and swine, with pharmacological evidence for a GHRP-like receptor. That paper did not test an FSD blend or a CJC-1295/ipamorelin combination.
Two ingredients with individually described activity do not automatically establish the behaviour of their mixture. A blend assessment needs the identities and amounts of both components, suitable analysis of the combined sample, and evidence addressing any claimed combined effect. “Synergy” requires a relevant comparison; it cannot be inferred from the existence of two citations.
How to assess the FSD listings and available reports
The DAC status of FSD’s CJC-1295 catalogue material is unconfirmed in the documentation used for this article. Do not treat this page as confirmation that the listing matches clinical CJC-1295. Check the product specification and original report, then ask for clarification if the sequence or linker status is missing.
Record the named analyte, terminal modifications, identity method, reported purity, quantity and sample or batch identifier. For the blend, look for separate component information. A verified laboratory record authenticates that record and its specified sample; linking it to current stock requires separate traceability evidence.
Keep the paper, product specification and sample report as distinct records in the same research file. Mark unresolved identity or stock-lot connections explicitly. FSD materials are intended for laboratory research, not human or veterinary administration.
Common questions
Does a CJC-1295 title mean the study tested no-DAC material?
No. Check the described structure. The foundational long-acting research used an albumin-binding extension; an abbreviated title does not establish equivalence.
Can a published half-life be applied to any CJC-1295 vial?
No. A pharmacokinetic estimate belongs to the studied chemical form and conditions. Resolve material identity before using it to interpret another sample.
Does preserved GH pulsatility prove clinical benefit?
No. It describes a secretion pattern. The cited physiology study did not establish a recovery, sleep or longevity outcome.
Does this article confirm whether FSD CJC-1295 contains DAC?
No. That status remains unconfirmed here. Request the exact specification and supporting identity documentation for the material under review.
Sources & scope
These references explain analytical and research principles. They do not certify FSD BIO LABS or provide evidence about a particular FSD batch.
- Identification of CJC-1295 as a long-lasting GRF analogue (2005) — Jetté et al. · Endocrinology
Primary cell-and-rat study defining CJC-1295’s albumin-binding extension and experimental activity. Abstract verified; no FSD sample identification or human efficacy claim. - Prolonged GH and IGF-I stimulation by CJC-1295 in healthy adults (2006) — Teichman et al. · Journal of Clinical Endocrinology & Metabolism
Two randomised human studies of long-acting CJC-1295, with GH/IGF-I and pharmacokinetic endpoints. Abstract verified; no catalogue-vial equivalence or long-term benefit–risk conclusion. - GH pulsatility during stimulation by long-acting CJC-1295 (2006) — Ionescu and Frohman · Journal of Clinical Endocrinology & Metabolism
Primary human physiology abstract: GH pulses persisted while trough and mean levels increased. Neither a no-DAC comparison nor a blend trial. - Identification of a CJC-1295-labelled peptide in an unknown preparation (2010) — Henninge et al. · Drug Testing and Analysis
Primary analytical abstract identifying a 29-residue amidated peptide in one preparation. Illustrates naming ambiguity; does not identify other suppliers’ products. - Ipamorelin: primary secretagogue pharmacology (1998) — Raun et al. · European Journal of Endocrinology
Primary abstract: ipamorelin pharmacology in rat pituitary cells, rats and swine. No CJC-1295 combination or FSD-blend assessment.